In an article published in USA TODAY, Jefferson is mentioned as one of a handful of leading oncology centers around the country that use genomic tests to help women make more informed treatment decisions, and to help doctors pick the right medicine for each patient.
The article describes a new test, called Guardant 360, which was approved for commercial use last year. The test makes use of blood sample instead of a tissue biopsy to detect trace amount of cancer DNA. That DNA is then analyzed for cancer-specific changes that can make tumors more aggressive, but can also identify a cancer’s Achilles’ heel — mutations that can be hit with newer gene-targeted therapies.
The test is one of several methods to peer into the ever-changing landscape of a tumor’s genome and ensure that a patient is getting the most effective medicine for his or her cancer.